Krystal Biotech, Inc.: share-based compensation expense
Share-based compensation expense for Krystal Biotech, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Krystal Biotech, Inc. financial histories
What this measure means
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
Exact concept: us-gaap:ShareBasedCompensation. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2016-01-01 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 54,514,000 | USD | 2026-02-17 | 10-K · 0001711279-26-000016 |
| 2024-01-01 | 2024-12-31 | 49,127,000 | USD | 2026-02-17 | 10-K · 0001711279-26-000016 |
| 2023-01-01 | 2023-12-31 | 39,933,000 | USD | 2026-02-17 | 10-K · 0001711279-26-000016 |
| 2022-01-01 | 2022-12-31 | 33,230,000 | USD | 2025-02-19 | 10-K · 0001711279-25-000008 |
| 2021-01-01 | 2021-12-31 | 15,319,000 | USD | 2024-02-26 | 10-K · 0001711279-24-000005 |
| 2020-01-01 | 2020-12-31 | 3,272,000 | USD | 2023-02-27 | 10-K · 0001711279-23-000008 |
| 2019-01-01 | 2019-12-31 | 1,239,000 | USD | 2021-03-01 | 10-K · 0001711279-21-000006 |
| 2018-01-01 | 2018-12-31 | 792,000 | USD | 2020-03-10 | 10-K · 0001564590-20-009550 |
| 2017-01-01 | 2017-12-31 | 246,000 | USD | 2018-03-12 | 10-K · 0001564590-18-005252 |
| 2016-01-01 | 2016-12-31 | 33,000 | USD | 2018-03-12 | 10-K · 0001564590-18-005252 |
Related financial histories
- Krystal Biotech, Inc.: total assets
- Krystal Biotech, Inc.: total liabilities
- Krystal Biotech, Inc.: stockholders equity
- Krystal Biotech, Inc.: cash and cash equivalents
- Krystal Biotech, Inc.: net income or loss
- Krystal Biotech, Inc.: operating cash flow
- Krystal Biotech, Inc.: capital expenditure payments
- Krystal Biotech, Inc.: contract revenue excluding tax
- Krystal Biotech, Inc.: financing cash flow
- Krystal Biotech, Inc.: investing cash flow
- Krystal Biotech, Inc.: retained earnings or deficit
- Krystal Biotech, Inc.: basic weighted-average shares
- Krystal Biotech, Inc.: diluted weighted-average shares
- Krystal Biotech, Inc.: basic earnings per share
- Krystal Biotech, Inc.: diluted earnings per share
- Krystal Biotech, Inc.: income tax expense or benefit
- Krystal Biotech, Inc.: net property, plant and equipment
- Krystal Biotech, Inc.: operating income or loss
- Krystal Biotech, Inc.: current assets
- Krystal Biotech, Inc.: interest expense
- Krystal Biotech, Inc.: current liabilities
- Krystal Biotech, Inc.: current accounts payable
- Krystal Biotech, Inc.: net current accounts receivable
- Krystal Biotech, Inc.: operating expenses
- Krystal Biotech, Inc.: net inventory
- Krystal Biotech, Inc.: selling, general and administrative expense
- Krystal Biotech, Inc.: research and development expense
Inspect the source
- Entity
- Krystal Biotech, Inc. / CIK 0001711279
- Captured
- 2026-09-21T17:24:26.140Z
- SEC response SHA-256
59dd6f5a8527c546b97edb976fee4c671180a1dc08a8dd5a9226eb1fbe912bc2
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001711279.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))